KalVista Pharmaceuticals (KALV) Return on Capital Employed (2015 - 2025)
KalVista Pharmaceuticals (KALV) reported Return on Capital Employed of 104.78% for Q3 2025, down 2516.0% on a YoY basis from 4.34% in Q3 2024, and down 23.25% sequentially from 85.01% in Q2 2025.
KalVista Pharmaceuticals (KALV) Return on Capital Employed (2015 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 11 years of Return on Capital Employed data on file, last reported at 104.78% in Q3 2025.
- For the quarter ending Q3 2025, Return on Capital Employed fell 2516.0% year-over-year to 104.78%; the trailing twelve-month figure through Jul 2025 stood at 104.78% (down 2516.0% YoY), and the FY2025 full-year result was 94.99%, down 1968.0% from the prior year.
- Return on Capital Employed declined to 104.78% in Q3 2025, from 85.01% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 24.48% in Q3 2021 to a low of 115.38% in Q1 2024.
- A 5-year average of 69.27% and a median of 68.82% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 3914 bps in 2021 and slumped 5361 bps in 2024, its largest moves.
- Tracing KALV's Return on Capital Employed over 5 years: stood at 30.58% in 2021, then plunged by 114 bps to 65.54% in 2022, then slumped by 36 bps to 89.17% in 2023, then fell by 22 bps to 108.39% in 2024, then increased by 3 bps to 104.78% in 2025.
- Business Quant data shows KALV's Return on Capital Employed at 104.78% in Q3 2025, 85.01% in Q2 2025, and 108.39% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -104.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -104.78% |
| Apr 30, 2025 | -85.01% |
| Oct 31, 2024 | -108.39% |
| Jul 31, 2024 | -79.62% |
| Apr 30, 2024 | -92.47% |
| Jan 31, 2024 | -115.38% |
| Oct 31, 2023 | -89.17% |
| Jul 31, 2023 | -72.10% |
| Apr 30, 2023 | -62.18% |
| Jan 31, 2023 | -61.76% |
| Oct 31, 2022 | -65.54% |
| Jul 31, 2022 | -56.40% |
| Apr 30, 2022 | -47.62% |
| Jan 31, 2022 | -39.08% |
| Oct 31, 2021 | -30.58% |
| Jul 31, 2021 | -24.48% |
| Apr 30, 2021 | -36.35% |
| Jan 31, 2021 | -75.94% |
| Oct 31, 2020 | -69.73% |
| Jul 31, 2020 | -56.94% |